Xuezhikang Therapy Increases miR-33 Expression in Patients with Low HDL-C Levels

Table 2

Changes of lipid profiles after Xuezhikang treatment.

Lipid profiles	Baseline		Aftertreatment		Percent change	𝑃 value
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)
TC, mmol/L	5.54 (0.76)	5.57 (4.93–6.07)	4.96 (0.63)	4.90 (4.44–5.96)	−10.5%	<0.001*
HDL-C, mmol/L	1.07 (0.13)	1.11 (0.95–1.18)	1.19 (0.13)	1.19 (1.12–1.30)	11.2%	<0.001*
LDL-C, mmol/L	3.35 (0.72)	3.38 (2.85–3.98)	2.86 (0.48)	2.86 (2.51–3.12)	−14.6%	<0.001*
HDL-C/LDL-C ratio	0.33 (0.07)	0.30 (0.29–0.36)	0.43 (0.07)	0.43 (0.39–0.47)	30.3%	<0.001*
TG, mmol/L	3.32 (1.92)	2.85 (2.16–3.97)	2.21 (0.94)	2.21 (1.39–2.80)	−22.5%	<0.001^†

SD: standard deviation; IQR: interquartile range; TC: total plasma cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides.
^∗𝑃 values for paired 𝑡-test.
^†𝑃 values for Wilcoxon signed rank test.